Robinson Michael R

Stamer W Daniel, Perkumas Kristin M, Kang Min H, Dibas Mohammed, Robinson Michael R, Rhee Douglas J

This study found high-concentration bimatoprost, like that from implants, dramatically upregulates MMPs in outflow tissues, potentially explaining sustained IOP lowering and outflow remodeling, even after drug clearance.

Medeiros Felipe A, Walters Thomas R, Kolko Miriam, Coote Michael, Bejanian Marina, Goodkin Margot L et al.

This study found bimatoprost implants effectively lowered IOP like timolol, but the 15μg dose had higher corneal risks. The 10μg implant shows promise for glaucoma adherence, balancing efficacy and safety.

Shen Jie, Robinson Michael R, Struble Craig, Attar Mayssa

Bimatoprost sustained-release implants in dogs showed dose-dependent IOP lowering for at least 3 months. The PK/PD correlation translates to humans, suggesting 8-15 µg doses for clinical development.

Lee Susan S, Robinson Michael R, Weinreb Robert N

Topical PGAs increase episcleral venous pressure (EVP), limiting IOP reduction, whereas intracameral PGAs decrease EVP, enhancing IOP lowering. This suggests EVP modulation is key for glaucoma treatment.